Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Otsuka Pharmaceutical Co., Ltd.

6 clinical trials · 6 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Otsuka Pharmaceutical Co., Ltd.

RECRUITINGNCT05342493

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be...

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 10001 location
Migraine Disorders
RECRUITINGPhase 3NCT07225712

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

To evaluate the safety of SEP-363856 (75 mg/day or 100 mg/day) administered for 52 weeks in adult participants with schizophrenia

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 1001 location
Schizophrenia
RECRUITINGPhase 3NCT05325645

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 4501 location
Acute Schizophrenia
RECRUITINGPhase 3NCT06926829

A Long-term Trial of EB-1020 in Adult Patients With ADHD

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial...

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 1801 location
Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITINGPhase 2 / Phase 3NCT07086313

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 3151 location
Attention-Deficit Hyperactivity Disorder(ADHD)
RECRUITINGNCT07053891

LUPKYNIS Drug-use Results Survey

The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.

Sponsor: Otsuka Pharmaceutical Co., Ltd.Enrolling: 4001 location
Lupus Nephritis